Therapeutic vaccination refocuses t-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)
<p><strong>Background:</strong> Strong and broad antiviral T-cell responses targeting vulnerable sites of HIV-1 will likely be a critical component for any effective cure strategy.</p> <p><strong>Methods:</strong> BCN01 trial was a phase I, open-label, non-r...
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Μορφή: | Journal article |
| Έκδοση: |
Elsevier
2019
|
| _version_ | 1826264864413188096 |
|---|---|
| author | Mothe, B Manzardo, C Sanchez-Bernabeu, A Coll, P Morón-López, S Puertas, MC Rosas-Umbert, M Cobarsi, P Escrig, R Perez-Alvarez, N Ruiz, I Rovira, C Meulbroek, M Crook, A Borthwick, N Wee, EG Yang, H Miró, JM Dorrell, L Clotet, B Martinez-Picado, J Brander, C Hanke, T BCN 01 study group |
| author_facet | Mothe, B Manzardo, C Sanchez-Bernabeu, A Coll, P Morón-López, S Puertas, MC Rosas-Umbert, M Cobarsi, P Escrig, R Perez-Alvarez, N Ruiz, I Rovira, C Meulbroek, M Crook, A Borthwick, N Wee, EG Yang, H Miró, JM Dorrell, L Clotet, B Martinez-Picado, J Brander, C Hanke, T BCN 01 study group |
| author_sort | Mothe, B |
| collection | OXFORD |
| description | <p><strong>Background:</strong> Strong and broad antiviral T-cell responses targeting vulnerable sites of HIV-1 will likely be a critical component for any effective cure strategy.</p> <p><strong>Methods:</strong> BCN01 trial was a phase I, open-label, non-randomized, multicenter study in HIV-1-positive individuals diagnosed and treated during early HIV-1 infection to evaluate two vaccination regimen arms, which differed in the time (8 versus 24 week)between the ChAdV63.HIVconsv prime and MVA.HIVconsv boost vaccinations. The primary outcome was safety. Secondary endpoints included frequencies of vaccine-induced IFN-γ+ CD8+ T cells, in vitro virus-inhibitory capacity, plasma HIV-1 RNA and total CD4+ T-cells associated HIV-1 DNA. (NCT01712425).</p> <p><strong>Findings:</strong> No differences in safety, peak magnitude or durability of vaccine-induced responses were observed between long and short interval vaccination arms. Grade 1/2 local and systemic post-vaccination events occurred in 22/24 individuals and resolved within 3 days. Weak responses to conserved HIV-1 regions were detected in 50% of the individuals before cART initiation, representing median of less than 10% of their total HIV-1-specific T cells. All participants significantly elevated these subdominant T-cell responses, which after MVA.HIVconsv peaked at median (range)of 938 (73-6,805)IFN-γ SFU/106 PBMC, representing on average 58% of their total anti-HIV-1 T cells. The decay in the size of the HIV-1 reservoir was consistent with the first year of early cART initiation in both arms.</p> <p><strong>Interpretation:</strong> Heterologous prime-boost vaccination with ChAdV63-MVA/HIVconsv was well-tolerated and refocused pre-cART T-cell responses towards more protective epitopes, in which immune escape is frequently associated with reduced HIV-1 replicative fitness and which are common to most global HIV-1 variants. Funding: HIVACAT Catalan research program for an HIV vaccine and Fundació Gloria Soler. Vaccine manufacture was jointly funded by the Medical Research Council (MRC)UK and the UK Department for International Development (DFID)under the MRC/DFID Concordat agreements (G0701669.</p> <p><strong>Research in Context:</strong> Evidence Before this Study: T cells play an important role in the control of HIV infection and may be particularly useful for HIV-1 cure by killing cells with reactivated HIV-1. Evidence is emerging that not all T-cell responses are protective and mainly only those targeting conserved regions of HIV-1 proteins are effective, but typically immunologically subdominant, while those recognizing hypervariable, easy-to-escape immunodominant ‘decoys’ do not control viremia and do not protect from a loss of CD4 T cells. We pioneered a vaccine strategy focusing T-cell responses on the most conserved regions of the HIV-1 proteome using an immunogen designated HIVconsv. T cells elicited by the HIVconsv vaccines in HIV-uninfected UK and Kenyan adults inhibited in vitro replication of HIV-1 isolates from 4 major global clades A, B, C and D.</p> <p><strong>Added Value of this Study:</strong> The present study demonstrated the concept that epitopes subdominant in natural infection, when taken out of the context of the whole HIV-1 proteome and presented to the immune system by a potent simian adenovirus prime-poxvirus MVA boost regimen, can induce strong responses in patients on antiretroviral treatment and efficiently refocus HIV-1-specific T-cells to the protective epitopes delivered by the vaccine.</p> <p><strong>Implications of all the Available Evidence:</strong> Nearly all HIV-1 vaccine strategies currently emphasize induction of broadly neutralizing Abs. The HIVconsv vaccine is one of a very few approaches focussing exclusively on elicitation of T cells and, therefore, can complement antibody induction for better prevention and cure. Given the cross-clade reach on the HIVconsv immunogen design, if efficient, the HIVconsv vaccines could be deployed globally. Effective vaccines will likely be a necessary component in combination with other available preventive measures for halting the HIV-1/AIDS epidemic.</p> |
| first_indexed | 2024-03-06T20:14:42Z |
| format | Journal article |
| id | oxford-uuid:2bc0903c-90ba-4baf-8000-402dce76e2ac |
| institution | University of Oxford |
| last_indexed | 2024-03-06T20:14:42Z |
| publishDate | 2019 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:2bc0903c-90ba-4baf-8000-402dce76e2ac2022-03-26T12:32:55ZTherapeutic vaccination refocuses t-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2bc0903c-90ba-4baf-8000-402dce76e2acSymplectic Elements at OxfordElsevier2019Mothe, BManzardo, CSanchez-Bernabeu, AColl, PMorón-López, SPuertas, MCRosas-Umbert, MCobarsi, PEscrig, RPerez-Alvarez, NRuiz, IRovira, CMeulbroek, MCrook, ABorthwick, NWee, EGYang, HMiró, JMDorrell, LClotet, BMartinez-Picado, JBrander, CHanke, TBCN 01 study group<p><strong>Background:</strong> Strong and broad antiviral T-cell responses targeting vulnerable sites of HIV-1 will likely be a critical component for any effective cure strategy.</p> <p><strong>Methods:</strong> BCN01 trial was a phase I, open-label, non-randomized, multicenter study in HIV-1-positive individuals diagnosed and treated during early HIV-1 infection to evaluate two vaccination regimen arms, which differed in the time (8 versus 24 week)between the ChAdV63.HIVconsv prime and MVA.HIVconsv boost vaccinations. The primary outcome was safety. Secondary endpoints included frequencies of vaccine-induced IFN-γ+ CD8+ T cells, in vitro virus-inhibitory capacity, plasma HIV-1 RNA and total CD4+ T-cells associated HIV-1 DNA. (NCT01712425).</p> <p><strong>Findings:</strong> No differences in safety, peak magnitude or durability of vaccine-induced responses were observed between long and short interval vaccination arms. Grade 1/2 local and systemic post-vaccination events occurred in 22/24 individuals and resolved within 3 days. Weak responses to conserved HIV-1 regions were detected in 50% of the individuals before cART initiation, representing median of less than 10% of their total HIV-1-specific T cells. All participants significantly elevated these subdominant T-cell responses, which after MVA.HIVconsv peaked at median (range)of 938 (73-6,805)IFN-γ SFU/106 PBMC, representing on average 58% of their total anti-HIV-1 T cells. The decay in the size of the HIV-1 reservoir was consistent with the first year of early cART initiation in both arms.</p> <p><strong>Interpretation:</strong> Heterologous prime-boost vaccination with ChAdV63-MVA/HIVconsv was well-tolerated and refocused pre-cART T-cell responses towards more protective epitopes, in which immune escape is frequently associated with reduced HIV-1 replicative fitness and which are common to most global HIV-1 variants. Funding: HIVACAT Catalan research program for an HIV vaccine and Fundació Gloria Soler. Vaccine manufacture was jointly funded by the Medical Research Council (MRC)UK and the UK Department for International Development (DFID)under the MRC/DFID Concordat agreements (G0701669.</p> <p><strong>Research in Context:</strong> Evidence Before this Study: T cells play an important role in the control of HIV infection and may be particularly useful for HIV-1 cure by killing cells with reactivated HIV-1. Evidence is emerging that not all T-cell responses are protective and mainly only those targeting conserved regions of HIV-1 proteins are effective, but typically immunologically subdominant, while those recognizing hypervariable, easy-to-escape immunodominant ‘decoys’ do not control viremia and do not protect from a loss of CD4 T cells. We pioneered a vaccine strategy focusing T-cell responses on the most conserved regions of the HIV-1 proteome using an immunogen designated HIVconsv. T cells elicited by the HIVconsv vaccines in HIV-uninfected UK and Kenyan adults inhibited in vitro replication of HIV-1 isolates from 4 major global clades A, B, C and D.</p> <p><strong>Added Value of this Study:</strong> The present study demonstrated the concept that epitopes subdominant in natural infection, when taken out of the context of the whole HIV-1 proteome and presented to the immune system by a potent simian adenovirus prime-poxvirus MVA boost regimen, can induce strong responses in patients on antiretroviral treatment and efficiently refocus HIV-1-specific T-cells to the protective epitopes delivered by the vaccine.</p> <p><strong>Implications of all the Available Evidence:</strong> Nearly all HIV-1 vaccine strategies currently emphasize induction of broadly neutralizing Abs. The HIVconsv vaccine is one of a very few approaches focussing exclusively on elicitation of T cells and, therefore, can complement antibody induction for better prevention and cure. Given the cross-clade reach on the HIVconsv immunogen design, if efficient, the HIVconsv vaccines could be deployed globally. Effective vaccines will likely be a necessary component in combination with other available preventive measures for halting the HIV-1/AIDS epidemic.</p> |
| spellingShingle | Mothe, B Manzardo, C Sanchez-Bernabeu, A Coll, P Morón-López, S Puertas, MC Rosas-Umbert, M Cobarsi, P Escrig, R Perez-Alvarez, N Ruiz, I Rovira, C Meulbroek, M Crook, A Borthwick, N Wee, EG Yang, H Miró, JM Dorrell, L Clotet, B Martinez-Picado, J Brander, C Hanke, T BCN 01 study group Therapeutic vaccination refocuses t-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study) |
| title | Therapeutic vaccination refocuses t-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study) |
| title_full | Therapeutic vaccination refocuses t-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study) |
| title_fullStr | Therapeutic vaccination refocuses t-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study) |
| title_full_unstemmed | Therapeutic vaccination refocuses t-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study) |
| title_short | Therapeutic vaccination refocuses t-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study) |
| title_sort | therapeutic vaccination refocuses t cell responses towards conserved regions of hiv 1 in early treated individuals bcn 01 study |
| work_keys_str_mv | AT motheb therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT manzardoc therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT sanchezbernabeua therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT collp therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT moronlopezs therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT puertasmc therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT rosasumbertm therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT cobarsip therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT escrigr therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT perezalvarezn therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT ruizi therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT rovirac therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT meulbroekm therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT crooka therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT borthwickn therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT weeeg therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT yangh therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT mirojm therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT dorrelll therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT clotetb therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT martinezpicadoj therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT branderc therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT hanket therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study AT bcn01studygroup therapeuticvaccinationrefocusestcellresponsestowardsconservedregionsofhiv1inearlytreatedindividualsbcn01study |